Piramal Pharma Ltd (PPLPHARMA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1003728, "name": "Piramal Pharma", "stock_name": "Piramal Pharma", "full_name": "Piramal Pharma Ltd", "name_url": "stocks-analysis/piramal-pharma", "exchange": 1, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "155.06", "chg": 3.33, "chgp": "2.19%", "dir": 1, "prev_price": "151.73", "mcapval": "20,284.00 Cr", "mcap": "Small Cap", "scripcode": 543635, "symbol": "PPLPHARMA", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE0DK501011", "curr_date": "Feb 02", "curr_time": "", "bse_nse_vol": "23.29 lacs", "exc_status": "Active", "traded_date": "Feb 02, 2026", "traded_date_str": "2026 02 02", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/piramal-pharma-1003728-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Piramal Pharma Gains 2.08%: 4 Key Factors Driving the Week’s Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-gains-208-4-key-factors-driving-the-weeks-volatility-3812665", "imagepath": "", "date": "2026-01-31 11:00:11", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Jan 27:</strong> New 52-week low hit at Rs.150.15</p>\n <p><strong>Jan 28:</strong> Sharp surge in open interest signalling bearish market positioning</p>\n <p><strong>Jan 29:</strong> Further 52-week low recorded at Rs.148.3 amid volatile trading</p>\n <p><strong>Jan 30:</strong> Week closes at Rs.154.55, up 2.08% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.151.40</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs..." }, { "title": "Piramal Pharma Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/piramal-pharma-ltd-is-rated-strong-sell-3812395", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/PiramalPharmaLt_mojoScore_3812395.png", "date": "2026-01-31 10:10:48", "description": "Piramal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Are Piramal Pharma Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-piramal-pharma-ltd-latest-results-good-or-bad-3810126", "imagepath": "", "date": "2026-01-29 19:25:29", "description": "Piramal Pharma Ltd's latest financial results for Q3 FY26 reveal significant operational challenges. The company reported a consolidated net loss of ₹136.19 crores, marking a substantial decline compared to the previous year. Revenue for the quarter was ₹2,139.87 crores, reflecting a year-on-year decrease of 2.92%, although there was a sequential growth of 4.70% from the previous quarter. This indicates a concerning trend of weakening demand across its key business segments, which include contract development and manufacturing, complex hospital generics, and India consumer healthcare.\n\nThe operating margin (excluding other income) fell to 9.15%, down from 15.32% in the same quarter last year, highlighting severe margin compression. The profit before tax also turned negative, with a loss of ₹93.86 crores compared to a profit in the previous year. Employee costs have risen, reflecting ongoing investment in ta..." }, { "title": "Piramal Pharma Q3 FY26: Losses Deepen as Operational Challenges Mount", "link": "https://www.marketsmojo.com/news/result-analysis/piramal-pharma-q3-fy26-losses-deepen-as-operational-challenges-mount-3809542", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/PiramalPharma_quaterlyResult_3809542.png", "date": "2026-01-29 10:35:55", "description": "Piramal Pharma Ltd. reported a consolidated net loss of ₹136.19 crores for Q3 FY26, marking a dramatic deterioration from the ₹3.68 crores profit posted in the same quarter last year. The loss widened 37.26% sequentially from Q2 FY26's ₹99.22 crores, highlighting deepening operational challenges at the ₹20,610 crores market capitalisation pharmaceutical company. The stock tumbled 3.18% to ₹159.15 following the results announcement, reflecting investor concerns over persistent profitability pressures despite modest revenue growth." }, { "title": "Piramal Pharma Ltd Stock Falls to 52-Week Low of Rs.148.3", "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-stock-falls-to-52-week-low-of-rs1483-3809343", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/PiramalPharmaLt_priceRelatedfactors_3809343.png", "date": "2026-01-29 10:08:43", "description": "Piramal Pharma Ltd’s shares touched a new 52-week low of Rs.148.3 today, marking a significant decline amid a challenging year for the pharmaceutical company. Despite a modest recovery over the past three days, the stock remains under pressure, reflecting ongoing concerns about its financial performance and valuation metrics." }, { "title": "Are Piramal Pharma Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-piramal-pharma-ltd-latest-results-good-or-bad-3808273", "imagepath": "", "date": "2026-01-28 19:19:53", "description": "Piramal Pharma Ltd's latest financial results for Q2 FY26 reflect significant operational challenges. The company reported a net loss of ₹99.22 crores, which marks a considerable deterioration compared to the previous year. Additionally, net sales amounted to ₹2,043.72 crores, indicating an 8.83% decline year-on-year, although there was a sequential growth of 5.69% from the previous quarter. \n\nThe operating margin has contracted sharply to 7.76%, down from 15.24% in the same quarter last year, highlighting severe profitability pressures. This margin compression is attributed to a combination of subdued revenue growth and increased operational costs. The gross profit margin also fell to 6.94%, further underscoring the pricing pressures or unfavorable product mix the company is experiencing.\n\nPiramal Pharma's financial performance has raised concerns regarding its ability to generate sustainable profits, as e..." }, { "title": "Piramal Pharma Ltd Sees Sharp Open Interest Surge Amid Bearish Market Positioning", "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-sees-sharp-open-interest-surge-amid-bearish-market-positioning-3807948", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/PiramalPharmaLt_oi_spurts_by_underlying_3807948.png", "date": "2026-01-28 15:00:31", "description": "Piramal Pharma Ltd (PPLPHARMA) has witnessed a significant 22.64% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this spike, the stock remains close to its 52-week low, reflecting ongoing bearish sentiment amid subdued price momentum and cautious investor participation." }, { "title": "Piramal Pharma Ltd Sees Sharp Open Interest Surge Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-sees-sharp-open-interest-surge-amid-mixed-market-signals-3807856", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/PiramalPharmaLt_oi_spurts_by_underlying_3807856.png", "date": "2026-01-28 14:00:22", "description": "Piramal Pharma Ltd (PPLPHARMA) has witnessed a notable 13.7% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading close to its 52-week low, the stock has outperformed its sector in recent sessions, reflecting a complex interplay of cautious optimism and bearish undertones among traders." }, { "title": "Piramal Pharma Ltd Sees Significant Open Interest Surge Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-sees-significant-open-interest-surge-amid-mixed-market-signals-3807791", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/PiramalPharmaLt_oi_spurts_by_underlying_3807791.png", "date": "2026-01-28 13:00:23", "description": "Piramal Pharma Ltd (PPLPHARMA) has witnessed a notable 12.23% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading close to its 52-week low, the stock has outperformed its sector in recent sessions, reflecting a complex interplay of cautious optimism and bearish undertones among traders." } ], "total": 385, "sid": "1003728", "stock_news_url": "https://www.marketsmojo.com/news/piramal-pharma-1003728" }, "announcements": "", "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Piramal Pharma Ltd has declared <strong>1%</strong> dividend, ex-date: 16 Jul 25", "dt": "2025-07-16", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "", "data": [ { "txt": "Piramal Pharma Ltd has announced <strong>5:46</strong> rights issue, ex-date: 02 Aug 23", "dt": "2023-08-02", "middle_text": "Rights Issue" } ] } ] }

Key Events This Week

Jan 27: New 52-week low hit at Rs.150.15

Jan 28: Sharp surge in open interest signalling bearish market positioning

Jan 29: Further 52-week low recorded at Rs.148.3 amid volatile trading

Jan 30: Week closes at Rs.154.55, up 2.08% for the week

Read full news article

Piramal Pharma Ltd is Rated Strong Sell

2026-01-31 10:10:48

Piramal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Are Piramal Pharma Ltd latest results good or bad?

2026-01-29 19:25:29

Piramal Pharma Ltd's latest financial results for Q3 FY26 reveal significant operational challenges. The company reported a consolidated net loss of ₹136.19 crores, marking a substantial decline compared to the previous year. Revenue for the quarter was ₹2,139.87 crores, reflecting a year-on-year decrease of 2.92%, although there was a sequential growth of 4.70% from the previous quarter. This indicates a concerning trend of weakening demand across its key business segments, which include contract development and manufacturing, complex hospital generics, and India consumer healthcare. The operating margin (excluding other income) fell to 9.15%, down from 15.32% in the same quarter last year, highlighting severe margin compression. The profit before tax also turned negative, with a loss of ₹93.86 crores compared to a profit in the previous year. Employee costs have risen, reflecting ongoing investment in ta...

Read full news article

Piramal Pharma Q3 FY26: Losses Deepen as Operational Challenges Mount

2026-01-29 10:35:55

Piramal Pharma Ltd. reported a consolidated net loss of ₹136.19 crores for Q3 FY26, marking a dramatic deterioration from the ₹3.68 crores profit posted in the same quarter last year. The loss widened 37.26% sequentially from Q2 FY26's ₹99.22 crores, highlighting deepening operational challenges at the ₹20,610 crores market capitalisation pharmaceutical company. The stock tumbled 3.18% to ₹159.15 following the results announcement, reflecting investor concerns over persistent profitability pressures despite modest revenue growth.

Read full news article

Piramal Pharma Ltd Stock Falls to 52-Week Low of Rs.148.3

2026-01-29 10:08:43

Piramal Pharma Ltd’s shares touched a new 52-week low of Rs.148.3 today, marking a significant decline amid a challenging year for the pharmaceutical company. Despite a modest recovery over the past three days, the stock remains under pressure, reflecting ongoing concerns about its financial performance and valuation metrics.

Read full news article

Are Piramal Pharma Ltd latest results good or bad?

2026-01-28 19:19:53

Piramal Pharma Ltd's latest financial results for Q2 FY26 reflect significant operational challenges. The company reported a net loss of ₹99.22 crores, which marks a considerable deterioration compared to the previous year. Additionally, net sales amounted to ₹2,043.72 crores, indicating an 8.83% decline year-on-year, although there was a sequential growth of 5.69% from the previous quarter. The operating margin has contracted sharply to 7.76%, down from 15.24% in the same quarter last year, highlighting severe profitability pressures. This margin compression is attributed to a combination of subdued revenue growth and increased operational costs. The gross profit margin also fell to 6.94%, further underscoring the pricing pressures or unfavorable product mix the company is experiencing. Piramal Pharma's financial performance has raised concerns regarding its ability to generate sustainable profits, as e...

Read full news article

Piramal Pharma Ltd Sees Sharp Open Interest Surge Amid Bearish Market Positioning

2026-01-28 15:00:31

Piramal Pharma Ltd (PPLPHARMA) has witnessed a significant 22.64% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this spike, the stock remains close to its 52-week low, reflecting ongoing bearish sentiment amid subdued price momentum and cautious investor participation.

Read full news article

Piramal Pharma Ltd Sees Sharp Open Interest Surge Amid Mixed Market Signals

2026-01-28 14:00:22

Piramal Pharma Ltd (PPLPHARMA) has witnessed a notable 13.7% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading close to its 52-week low, the stock has outperformed its sector in recent sessions, reflecting a complex interplay of cautious optimism and bearish undertones among traders.

Read full news article

Piramal Pharma Ltd Sees Significant Open Interest Surge Amid Mixed Market Signals

2026-01-28 13:00:23

Piramal Pharma Ltd (PPLPHARMA) has witnessed a notable 12.23% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading close to its 52-week low, the stock has outperformed its sector in recent sessions, reflecting a complex interplay of cautious optimism and bearish undertones among traders.

Read full news article